Labcorp Holdings Files Second Quarter 10-Q Report
The clinical laboratory and drug development company submitted its quarterly financial disclosures to the SEC as investors await upcoming dividend and earnings dates.
Quarterly Filing Submitted
Labcorp Holdings Inc. (LH) filed its quarterly report on Form 10-Q with the Securities and Exchange Commission on August 5, the regulatory disclosure shows. The filing provides investors with the company's financial performance and operational updates for the most recent quarter.
The $25 billion market cap diagnostics and drug development company, which closed at $312.34 in its most recent trading session, is required to submit the 10-Q disclosure within 40 days of quarter-end for large accelerated filers.
Upcoming Corporate Actions
According to MarginX data, Labcorp has scheduled a cash dividend of $0.72 per share for August 28, 2026. The dividend represents part of the company's regular capital return program to shareholders.
Investors will next hear from the company on October 29, 2026, when Labcorp is expected to report its third quarter 2026 results, MarginX data indicates. The earnings release will provide management commentary on business trends and financial performance heading into the final quarter of the year.
Insider Activity
Recent insider transactions show activity from Peter J. Wilkinson, according to MarginX data. Wilkinson exercised options for 1,338 shares and subsequently sold those 1,338 shares, along with an additional sale of 82 shares. Such transactions are routine disclosures required of corporate insiders and may be part of pre-planned trading programs.
Macro Context
The filing comes as market participants await monetary policy decisions from the Federal Reserve. The Federal Open Market Committee is scheduled to announce its rate decision along with economic projections on September 16, followed by another policy decision on October 28, according to MarginX data. These decisions could influence healthcare sector valuations and corporate borrowing costs as companies navigate the broader economic environment.
Labcorp operates clinical laboratories and provides drug development services, serving healthcare providers, pharmaceutical companies, and biotechnology firms across the United States.
This article was generated by MarginX from public news on 2026-08-05. It is not investment advice.